Combinatorial Landscape Analysis for
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Combinatorial Landscape Analysis for Dominating Set and Vertex Coloring
arXiv:2606.07361v1 Announce Type: new Abstract: We analyze the two combinatorial problems of Dominating Set and Vertex Coloring regarding what kind of local optima are present for various instances. For a variety of graph classes each, we determine whether the induced landscapes are unimodal, plateau-unimodal (all optima are just one plateau), equimodal (all local optima are global) or truly multimodal. We do this for two different neighborhood operators, one based on making only a single...
A Padding Method for Enhanced Encoding of Inorganic Structures with Varying Chemical Compositions
arXiv:2605.30743v1 Announce Type: cross Abstract: Designing novel inorganic materials through generative models remains an important challenge for material science, driven by the complexity and diversity of inorganic structures across expansive chemical compositions and structural landscape. The vast combinatorial space of inorganic compounds demands innovative, AI-driven approaches to overcome limitations in generative accuracy and efficiency.
A Padding Method for Enhanced Encoding of Inorganic Structures with Varying Chemical Compositions
arXiv:2605.30743v2 Announce Type: replace-cross Abstract: Designing novel inorganic materials through generative models remains an important challenge for material science, driven by the complexity and diversity of inorganic structures across expansive chemical compositions and structural landscape. The vast combinatorial space of inorganic compounds demands innovative, AI-driven approaches to overcome limitations in generative accuracy and efficiency.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.